HEPHAISTOS-Pharma
PrivateLast Round
Seed
May 16, 2024
Total Funding Raised
$4.88M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
HEPHAISTOS-Pharma operates in Healthcare & Life Sciences and is based in Orsay. Its latest recorded funding round was a Seed round in May 2024.
HEPHAISTOS-Pharma is a biotechnology company developing innovative oncology treatments through a platform that enhances immune responses and transforms cold tumors into targets for effective cancer therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HEPHAISTOS-Pharma Comparables
Compare HEPHAISTOS-Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tallac Therapeutics | 83% | |
| Stimunity | 81% | |
| Ipsen | 78% |
For institutional investors. Book with your work email.
HEPHAISTOS-Pharma Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
HEPHAISTOS-Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| France 2030 | Seed |
| European Innovation Council Fund | Seed |
| Noshaq | Seed |
| xista science ventures | Seed |
| Elaia Partners | Seed |
| Angels Santé | Seed |
| Femmes Business Angels | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Grew 19% QoQ, from 16 to 19 employees.
- May 16, 2024
$4.88M raised from Elaia Partners and Noshaq.
For institutional investors. Book with your work email.
HEPHAISTOS-Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about HEPHAISTOS-Pharma's valuation, stock price, and market status.
Is HEPHAISTOS-Pharma a public or private company?
HEPHAISTOS-Pharma is a private company.
What is the current stock price of HEPHAISTOS-Pharma?
HEPHAISTOS-Pharma is a private company, so its shares have no public market price. Caplight tracks HEPHAISTOS-Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HEPHAISTOS-Pharma worth (valuation)?
Valuation information for HEPHAISTOS-Pharma is not publicly available.
Can I buy HEPHAISTOS-Pharma stock?
HEPHAISTOS-Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HEPHAISTOS-Pharma's last funding round?
HEPHAISTOS-Pharma's most recent funding round was Seed on May 16, 2024.
Who are the main investors in HEPHAISTOS-Pharma?
Key investors in HEPHAISTOS-Pharma include Elaia Partners.
Will HEPHAISTOS-Pharma IPO soon?
No public IPO plans have been announced for HEPHAISTOS-Pharma.
How can I track HEPHAISTOS-Pharma secondary market activity?
Caplight tracks bids, offers, and trades in HEPHAISTOS-Pharma's shares on secondary markets.